Contact
Cap Sigma - ZAC Euromédecine II, 1682 Rue de la Valsière
34790 Grabels
France
Business development director
About us
Mabqi is a biotechnology company specializing in the discovery and development of human antibodies.
The company's core technologies is a synthetic library of several billion of highly developable and functional human antibodies combined to AI-powered phage and yeast display techniques. Leveraging our innovative discovery platform, we specialize in the discovery of monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), pH-sensitive antibodies and various other immunotherapy formats..
The company also develops a proprietary portfolio of first-in-class and best-in-class antibodies with high therapeutic potential in oncology.
Business offer
- Antibody discovery:
- - in vitro selection of readily-developable and functional antibodies that bind to target antigen with high specificity and affinity.
- This approach is suited for virtually any targets including ion channels, GPCRs, peptides, proteins, peptide-MHC complexes.
- - Comprehensive antibody hits’ characterization and functional validation
- pH-sensitive antibody discovery to target the tumor acidic micro-environment
Antibody maturation (based on a parental antibody lead) to improve binding affinity, specificity and interspecies cross-reactivity, enhance developability, to optimize therapeutic potency and functionality such as pH-sensitivity or internalization
Activities
- Therapeutic Product
- Service
- Cardiology
- Oncology
- Nervous Central System
- Hematology
- Infectiology
- Immunology
- Inflammation
- Hit discovery
- Screening & Identification
- Therapeutic libraries
- Bioinformatics prediction & analysis
- Immunotherapy lead generation
- Binding & Affinity
- Potency & Specificity
- Epitope mapping
- Functional effects
- ADCC, ADCP & CDC
- Antigen density target
- Internalization
- Immunotherapy lead optimization
- Engineering
- ADC
- Multi-, bispecific
- Antibody humanization
- Affinity maturation
- Proof of concept
- in-vitro & ex-vivo models
